Immune checkpoint therapy represented by PD-1/PD-L1 has achieved significant efficacy in tumors such as melanoma and non-small cell lung cancer, but its response rate in ovarian cancer clinical trials is less than 10% (37, 38), suggesting that the immunosuppressive microenvironment of ovarian cancer is complex. This evidence concerns the gene CD274 and ovarian carcinoma.